Table 3. All AEs resulting from TACE treatment in patients with HCC (N=36).
AEs | n (%) | |
Any grade | Grade 3 | |
AE, adverse event; TACE, transcatheter arterial chemoembolization; HCC, hepatocellular carcinoma. *, included elevation of transaminase, bilirubin and g-glutamyltranspeptidase. | ||
Abdominal pain | 27 (75.0) | 4 (11.1) |
Liver function injury* | 9 (25.0) | 0 (0) |
Nausea | 4 (11.1) | 0 (0) |
Abdominal distension | 3 (8.3) | 0 (0) |
Vomiting | 1 (2.8) | 0 (0) |
Appetite loss | 1 (2.8) | 0 (0) |